ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis

ClinicalTrials.gov ID: NCT01583374

Public ClinicalTrials.gov record NCT01583374. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 12:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS

Study identification

NCT ID
NCT01583374
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Amgen
Industry
Enrollment
490 participants

Conditions and interventions

Interventions

  • Apremilast tablet 20 mg Drug
  • Apremilast tablet 30 mg BID Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 1, 2012
Primary completion
Feb 23, 2014
Completion
Oct 24, 2018
Last update posted
May 11, 2020

2012 – 2018

United States locations

U.S. sites
20
U.S. states
13
U.S. cities
20
Facility City State ZIP Site status
Sun Valley Arthritis Center Peoria Arizona 85381
University of California, San Diego La Jolla California 92093-0943
Desert Medical Advances Palm Desert California 92260
UCSF Arthritis Center San Francisco California 94143-0326
Advent Clinical Research Centers, Inc Pinellas Park Florida 33781
Burnette & Silverfield, MDS PLC Tampa Florida 33614
Alastair Kennedy, MD Research Vero Beach Florida 32960
Northwestern Medical Faculty Foundation Chicago Illinois 60611
Klein and Associates MD, PA Cumberland Maryland 21502
Klein and Associates MD, PA Hagerstown Maryland 21740
Clinical Pharmacology Study Group Worcester Massachusetts 01605
Saint Paul Rheumatology, PA Eagan Minnesota 55121
MetroHealth Medical Systems Cleveland Ohio 44109
STAT Research, Inc. Dayton Ohio 45417
Altoona Center for Clinical Research Duncansville Pennsylvania 16635
The Arthritis Clinic Jackson Tennessee 38305
Ramesh C Gupta MD Memphis Tennessee 38119
Austin Regional Clinic Austin Texas 78731
University of Utah Hospitals and Clinics Salt Lake City Utah 84132
Rheumatology and Immunotherapy Center Franklin Wisconsin 53132

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 83 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01583374, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 11, 2020 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01583374 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →